Peak expiratory flow increases were greater with benralizumab than placebo in patients with severe eosinophilic asthma.
Results found that infants with an unknown epilepsy etiology, a normal MRI, an EEG displaying hypsarrhythmia, or those already receiving an AED were more likely to be administered ACTH.
Children with asthma who experience chronic oral glucocorticoid exposure may have significant morbidities, including adrenal suppression, recurrent pneumonia, and behavioral problems.
Omalizumab therapy was associated with reduced exacerbation and hospitalization rates in US clinics, according to findings from the prospective multicenter observational registry PROSPERO study
Reslizumab reduced the risk for exacerbations and improved lung function when compared to placebo, in patients with severe eosinophilic asthma.